Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPX NASDAQ:HCWB NASDAQ:LIMN NASDAQ:MTEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.86-0.8%$1.56$0.86▼$55.00$8.97M-0.941.04 million shs98,272 shsHCWBHCW Biologics$0.31-2.9%$0.47$0.25▼$17.80$2.09M1.136.28 million shs136,229 shsLIMNLiminatus Pharma$0.20+0.7%$0.21$0.16▼$33.66$9.07MN/A8.12 million shs333,493 shsMTEXMannatech$4.80+2.8%$5.95$4.28▼$12.45$9.26M0.6114,519 shs3,430 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex-2.84%-11.28%-36.86%-60.68%-93.82%HCWBHCW Biologics-8.62%-32.02%+17.33%-69.20%-95.43%LIMNLiminatus Pharma-2.20%-1.76%+8.67%-89.10%+20,049,900.00%MTEXMannatech-4.30%+6.62%-25.16%-36.81%-54.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.86-0.8%$1.56$0.86▼$55.00$8.97M-0.941.04 million shs98,272 shsHCWBHCW Biologics$0.31-2.9%$0.47$0.25▼$17.80$2.09M1.136.28 million shs136,229 shsLIMNLiminatus Pharma$0.20+0.7%$0.21$0.16▼$33.66$9.07MN/A8.12 million shs333,493 shsMTEXMannatech$4.80+2.8%$5.95$4.28▼$12.45$9.26M0.6114,519 shs3,430 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex-2.84%-11.28%-36.86%-60.68%-93.82%HCWBHCW Biologics-8.62%-32.02%+17.33%-69.20%-95.43%LIMNLiminatus Pharma-2.20%-1.76%+8.67%-89.10%+20,049,900.00%MTEXMannatech-4.30%+6.62%-25.16%-36.81%-54.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGenprex 1.00SellN/AN/AHCWBHCW Biologics 2.00Hold$35.0011,154.02% UpsideLIMNLiminatus Pharma 1.00SellN/AN/AMTEXMannatech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest HCWB, MTEX, GNPX, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GNPXGenprex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026HCWBHCW Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026LIMNLiminatus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGenprexN/AN/AN/AN/A$2.42 per shareN/AHCWBHCW Biologics$50K41.86N/AN/A$0.84 per share0.37LIMNLiminatus PharmaN/AN/AN/AN/A($0.36) per shareN/AMTEXMannatech$108.04M0.09N/AN/A($2.75) per share-1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGenprex-$16.23M-$26.50N/AN/AN/AN/A-464.05%-275.54%6/3/2026 (Estimated)HCWBHCW Biologics-$7.96M-$9.88N/AN/AN/A-14,472.73%N/A-51.05%N/ALIMNLiminatus Pharma-$10.21M-$0.15N/AN/AN/AN/AN/A-402.52%N/AMTEXMannatech-$15.21M-$8.00N/AN/AN/A-14.08%-398.35%-45.63%5/11/2026 (Estimated)Latest HCWB, MTEX, GNPX, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2026Q4 2025MTEXMannatechN/A-$5.94N/A-$5.94N/A$26.64 million3/31/2026Q4 2025HCWBHCW Biologics-$0.84-$2.63-$1.79-$1.02$7.01 million$0.03 million3/31/2026Q4 2025LIMNLiminatus PharmaN/A-$0.34N/A-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGenprexN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AMTEXMannatech$0.204.17%-100.00%N/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGenprexN/A3.843.84HCWBHCW BiologicsN/A0.110.11LIMNLiminatus PharmaN/A0.050.05MTEXMannatech0.481.100.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGenprex14.05%HCWBHCW Biologics2.96%LIMNLiminatus PharmaN/AMTEXMannatech12.98%Insider OwnershipCompanyInsider OwnershipGNPXGenprex0.44%HCWBHCW Biologics42.70%LIMNLiminatus PharmaN/AMTEXMannatech41.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGenprex2010.42 million10.37 millionNo DataHCWBHCW Biologics406.73 million3.86 millionNot OptionableLIMNLiminatus PharmaN/A44.88 millionN/AN/AMTEXMannatech2501.93 million1.13 millionNot OptionableHCWB, MTEX, GNPX, and LIMN HeadlinesRecent News About These CompaniesMannatech (NASDAQ:MTEX) Stock Passes Below 200 Day Moving Average - Here's What HappenedMay 5 at 3:56 AM | americanbankingnews.comMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | markets.businessinsider.comMannatech, Incorporated Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | quiverquant.comQMannatech Reports Financial Results for Fourth Quarter and Year Ended 2025April 17, 2026 | globenewswire.comMannatech, IncorporatedApril 8, 2026 | edition.cnn.comMannatech Delays 10-K Filing Amid Going-Concern ReviewApril 2, 2026 | tipranks.comMannatech Announces Notification of Late FilingApril 1, 2026 | markets.businessinsider.comMannatech Inc. Reports Improved Quarterly Earnings Amid Sales DeclineNovember 13, 2025 | msn.comMannatech Reports Financial Results for Third Quarter 2025November 12, 2025 | globenewswire.comMicro-Cap Mannatech Stock Draws Frenzied Retail Buzz As Traders Pounce On 'Tiny Float' PlayOctober 13, 2025 | msn.comMannatech Extends Loan Repayment to March 2027September 12, 2025 | tipranks.comMannatech trading halted, volatility trading pauseAugust 14, 2025 | msn.comMannatech Reports Financial Results for Second Quarter 2025August 12, 2025 | businesswire.comMannatech, Incorporated (MTEX) - Yahoo FinanceJuly 24, 2025 | finance.yahoo.comMannatech names Peter Griscom as new chief operating officerJune 27, 2025 | investing.comMannatech Announces Promotion of Peter Griscom to Chief Operating Officer - MorningstarJune 27, 2025 | morningstar.comMMannatech appoints Peter Griscom COOJune 26, 2025 | msn.comMannatech Announces Promotion of Peter Griscom to Chief Operating OfficerJune 26, 2025 | businesswire.comMannatech Announces Results of Annual Shareholders’ MeetingJune 5, 2025 | finance.yahoo.comMannatech Announces Results of Annual Shareholders' MeetingJune 5, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCWB, MTEX, GNPX, and LIMN Company DescriptionsGenprex NASDAQ:GNPX$0.86 -0.01 (-0.81%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.HCW Biologics NASDAQ:HCWB$0.31 -0.01 (-2.90%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Liminatus Pharma NASDAQ:LIMN$0.20 +0.00 (+0.75%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Mannatech NASDAQ:MTEX$4.80 +0.13 (+2.78%) As of 10:45 AM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
